Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the company ...

Exact Sciences Corporation EXAS is focused on further promoting Cologuard as the standard of care. The company prioritizes high-return pipeline opportunities with large patient impacts ...

(RTTNews) - Exact Sciences Corp. (EXAS) Monday has introduced Cologuard Plus, an FDA-approved noninvasive colorectal cancer - CRC screening test for average-risk adults aged 45 and older.

EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It developed Cologuard, a screening test for the early detection ...

We recently published a list of Billionaire George Soros’ 10 Small-Cap Stocks with Huge Upside Potential. In this article, we ...

Cell-free DNA § Ghigliotty attended the March 2025 Cologuard Classic through a grant from Exact Sciences to the GI Cancers Alliance, which has also received prior funding from the company.

Mizuho initiated coverage of Exact Sciences (EXAS) with an Outperform rating and $60 price target The firm is “bullish” given the launch in Q2 of the next-generation flagship Cologuard Plus ...

What a brutal six months it’s been for Exact Sciences. The stock has dropped 37.2% and now trades at $44.10, rattling many ...

“Exact Sciences is proud to share our latest research at DDW 2025, highlighting the effectiveness and strong predicted preference for Cologuard, reinforcing our continued leadership in CRC ...

EXACT Sciences Corp. is a cancer screening and ... It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX.